Guinea will inoculate all people who have come into contact with new cases of Ebola after successful trials of a vaccine developed by Merck & Co., the head of the campaign against the virus said. Guinea’s government, the World Health Organization and the medical charity Doctors Without Borders began a series of trials of the VSV-EBOV vaccine in the West African nation on March 7, National Coordinator of the Fight against Ebola in Guinea Sakoba Keita told reporters in the capital, Conakry.
“The vaccine showed a 100 percent efficacy,” Keita said. “From today, all the contacts will be vaccinated so as to stop the evolution of the virus.”
Ebola has killed more than 11,000 people in West Africa following an outbreak that began in late 2013. While the number of new cases has fallen off sharply, it hasn’t been eradicated, with seven confirmed cases in the week of July 29. The vaccine from Merck is one of several in clinical trials, with GlaxoSmithKline Plc and Novavax Inc. also developing medicines.